WO1997007110A1 - Process for producing taxol derivatives and intermediates therefor - Google Patents

Process for producing taxol derivatives and intermediates therefor Download PDF

Info

Publication number
WO1997007110A1
WO1997007110A1 PCT/US1996/012666 US9612666W WO9707110A1 WO 1997007110 A1 WO1997007110 A1 WO 1997007110A1 US 9612666 W US9612666 W US 9612666W WO 9707110 A1 WO9707110 A1 WO 9707110A1
Authority
WO
WIPO (PCT)
Prior art keywords
ester
acid
taxane
mmol
formula
Prior art date
Application number
PCT/US1996/012666
Other languages
French (fr)
Inventor
Yun Gao
Charles M. Zepp
Original Assignee
Sepracor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor, Inc. filed Critical Sepracor, Inc.
Priority to AU66464/96A priority Critical patent/AU6646496A/en
Publication of WO1997007110A1 publication Critical patent/WO1997007110A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Definitions

  • the invention relates to a process for the
  • Taxol (I) is currently in clinical trials and has demonstrated efficacy with manageable side
  • Taxol whose generic name as a drug is
  • paclitaxel is currently produced by extraction from the bark of the Pacific yew, Taxus brevifolia .
  • the Pacific yew is a slow growing conifer found in the understory of old growth stands in the Pacific
  • the azide is reduced, resulting in a trans-acylation from oxygen to nitrogen;
  • taxane is understood to encompass diterpenoids having a 6, 10-methanobenzocyclodecane ring structure oxygenated at least at the 3,5,8,11 and 12 positions and carbon-substituted at
  • the oxygen at position 8 of the methanobenzocyclodecane is an alcohol (which will be esterified) and the carbon at 4 and the oxygen at 3 are cyclized to form an oxetane ring.
  • Structure II above reflects the pattern of substitution of the taxanes of interest and shows the numbering system commonly used for taxol, which is different from the numbering system of the parent
  • the amino protecting group is then removed to
  • the invention relates to a process for the preparation of taxol, and derivatives thereof, comprising: (a) reacting a ⁇ -alkoxycarbonyl-aminophenylpropionic acid of formula (XII) wherein R 1 is C 1 to C 10 alkyl, phenyl or substituted phenyl; R 3 is hydrogen, loweralkyl, loweralkoxyl, di- loweralkylamino or halo; and R 4 is benzyl (Cbz), t-butyl (tBoc), allyl (Aloe), trichloroethyl (Troc), or 9-fluorenylmethyl (Fmoc), with a 13-hydroxy taxane to produce an amidophenylpropionic ester at C-13 of the taxane;
  • R 1 substituents are phenyl, substituted phenyl (particularly 4-chlorophenyl) or t-butoxyl; the preferred R 3 is hydrogen.
  • alkyl refers to saturated hydrocarbons
  • Lower alkyl refers to alkyl of six or fewer carbons.
  • the process of the invention relates to a process as above
  • R 2 is a protecting group for an alcohol.
  • protecting group for an alcohol refers to a residue that is stable under the conditions of the condensation of the benzenepropanoic acid with the 13-hydroxy taxane, but that can be cleaved to an alcohol under conditions that do not otherwise affect the ⁇ -amido- ⁇ -hydroxybenzenepropanoic ester of the taxane.
  • Suitable protecting groups include 1,1,1-trichloroethoxycarbonyl (Troc), removable by zinc in acetic acid and aryldialkylsilanes or trialklsilanes, removable by mild acid such as 0.5% HCl in methanol.
  • a preferred protecting group for the C-7 hydroxyl is trihexylsilyl .
  • the process of the invention may further comprise
  • protecting group R 2 to produce taxol and the step of deprotecting the ⁇ -aminobenzenepropanoic ester may also cleave the protecting group R 2 , whereby a 2',7-dihydroxy-3' -amidoester is produced in a single reaction.
  • the invention relates to compounds of formula XIV:
  • R 1 is C 1 to C 10 alkyl, C 1 to C 10 alkoxyl, phenyl or substituted phenyl;
  • R 3 is hydrogen, loweralkyl, loweralkoxyl, di-loweralkylamino or halo and
  • R 4 is allyl, benzyl, t-butyl, or 9-fluorenylmethyl.
  • Preferred compounds are those in which R 1 is phenyl, t-butoxyl or 4-chlorophenyl and R 3 is hydrogen.
  • the invention relates to compounds of formula XV
  • R 2 is trialkylsilyl (e.g. t-butyldimethylsilyl, trihexylsilyl, triethylsilyl or trimethylsilyl), or aryldialkylsilyl (e.g.
  • phenyldimethylsilyl and the other substituents are as defined before.
  • the compounds are useful as intermediates in the process of the invention.
  • the central process of the invention involves the reaction of a suitably protected 13-hydroxy-taxane X with a ⁇ -alkoxycarbonylamino-phenylpropionic acid XIV to form the ester XV.
  • the C-7 hydroxyl of baccatin is the most reactive hydroxyl and must commonly be protected during the reaction to form the ester. It will then be deprotected in a final step to produce taxol or a taxol analog.
  • Scheme B is a generic version of Scheme A:
  • chloroformate or equivalent such as di-t-butyl dicarbonate [(Boc) 2 O] under Schotten-Baumann
  • the ⁇ -alkoxycarbonyl-aminophenylpropionic acid can be synthesized from optically pure ethyl (2R,3S)-phenylglycidate, which is obtained by enzymatic resolution of the racemic glycidate according to the method of U.S. patent 5,274,300 or from ethyl
  • a base such as 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU).
  • DBU 1,8-diazabicyclo [5.4.0] undec-7-ene
  • the 3-azido-2-hydroxy ester is treated with an acid chloride (R 1 COCl), such as benzoyl chloride, to give the 3-azido-2-acyloxy ester which is then hydrogenated in the presence of di-alkyl-dicarbonate, such as Boc 2 O, under 1 atm of hydrogen over a catalyst, such as Pd/C, to give the 3-alkoxycarbonylamino-2-acyloxyphenylpropionic ester.
  • R 1 COCl acid chloride
  • benzoyl chloride such as benzoyl chloride
  • the condensation of the baccatin with the acid sidechain is performed using at least one equivalent of the acid in the presence of at least one equivalent of activating reagent such as dialkylcarbodiimide, di-2-pyridylcarbonate and PhOPOCl 2 or Me 2 NPOCl 2 and a base such as 4-dimethylaminopyridine (DMAP) or 4-pyrrolidinopyridine (4-PP) in an inert solvent.
  • DMAP 4-dimethylaminopyridine
  • 4-PP 4-pyrrolidinopyridine
  • the condensation is performed using 1.2- 1.5 equivalents of the acid XIV in the presence of 1.2-1.5 equivalents of DCC or DIC and 0.2-0.5 equivalents of DMAP or 4-PP in toluene at 40-50°C for 4-10 hours.
  • R 4 of the alkoxycarbonylaminophenylpropionic acid is t-butyl and R 2 of the 7-hydroxyl protecting group is a silyl group
  • condensation product to taxol and analogs is most conveniently accomplished in acidic medium such as trifluroacetic acid (TFA) in methylene dichloride or THF or in neat formic acid.
  • acidic medium such as trifluroacetic acid (TFA) in methylene dichloride or THF or in neat formic acid.
  • THF trifluroacetic acid
  • R 4 is benzyl, allyl, or 9-fluorenylmethyl and R 2 is silyl
  • the conversion is accomplished by removal of the silyl group with an acid, as above, or with HF/pyridine or with
  • 10-Deacetyl baccatin-III (10-DAB) was treated with a variety of reagents under a number of reaction conditions. It appears that silyl protecting groups were more well behaved than other common protecting groups. Treatment of 10-DAB with triethylsilyl chloride and imidazole in DMF resulted in the smooth preparation of the triethyl silyl ether in 70% yield. Under similar conditions, treatment with t-butylmethoxphenylsilyl bromide resulted in the silylated taxoid in a yield of 89%.
  • phenyldimethyl silyl derivative was prepared in an acceptable yield of 74%.
  • a preferred protecting group is tri-n-hexylsilyl.
  • 10-DAB Underwent smooth silylation to produce the C-7 silylated material in 80% yield.
  • acylation of the discrete alkoxide The more labile phenyldimethylsilyl group is cleaved to a greater extent than the trialkylsilyl ethers under the same reaction conditions.
  • the unoptimized yield for the acylation of the tri-n-hexylsilyl derivative is 70%.
  • the removal of the C-7 silyl protecting group may be accomplished by HF in pyridine, resulting in clean conversion to the free alcohol. Cleavage of the tri-n-hexylsilyl ether was slower than the triethylsilyl ether; the yield for the tri-n-hexylsilyl ether deprotection was 68%.
  • HF in acetonitrile proved too harsh and resulted in the production of a complex mixture of products.
  • Tri-n-hexylsilyl chloride has similar reactivity to triethylsilyl chloride and is cheaper than
  • the intermediate ether can be purified by recrystallization; and the protecting group can be cleanly cleaved.
  • Tetrabutylammonium fluoride in THF (1.0 M in THF, 57 mL) was added dropwise. The resulting solution was stirred at. room temperature for 7 h and concentrated to dryness. The residue was dissolved in 300 mL of EtOAc and acidified with 1 N H 2 SO 4 to pH 3-4.
  • reaction mixture was stirred for 2 h at 25°C. Ethyl acetate and water were added. After separation of the phases, the aqueous phase was extracted twice with ethyl acetate. The combined organic extracts were washed with saturated copper sulphate, water and brine, and dried over anhydrous magnesium sulphate. After filtration and removal of the solvent under reduced pressure, the residue was purified by flash chromatography on silica gel (elution with 70-100% ethyl acetate/hexanes) to yield 111 mg of pure baccatin III (68% yield).
  • Example 10 dicyclohexylcarbodiimide (DCC) (41 mg, 0.2 mmol), 4 -pyrrolidinopyridine (15 mg, 0.1 mmol) and 7- triethylsilyl baccatin (TES-baccatin) (70 mg, 0.1 mmol) in 0.3 mL of dry toluene was heated at 50 C for 6 h.
  • DCC dicyclohexylcarbodiimide
  • 4 -pyrrolidinopyridine 15 mg, 0.1 mmol
  • TES-baccatin 7- triethylsilyl baccatin
  • Example-4 As an alternative to example 5, the (2R, 3S)-3-azido-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester from.
  • Example-4 (6.2 g, 20.2 mmol) was treated with ammonium formate (5 g, 80 mmol) in the presence of 10% Pd/C (0.6 g) in 50 mL of methanol for 3-5 hours. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated to dryness. The residue was diluted with 150 mL of ethyl acetate and washed with water and sodium bicarbonate solution.
  • reaction mixture was diluted with 150 mL of ethyl acetate and washed with water, dilute sulfuric acid and sat'd NaCl solution.
  • the crude product was then purified on silica gel eluting with hexane and 10% ethyl acetate in hexane to give the (2R,3S)-3- benzyloxycarbonylamino-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.33 g, 41% yield).
  • reaction mixture was then cooled and purified on silica gel eluting with hexane and 15% ethyl
  • Taxol (9 mg) identical with natural taxol by HNMR and HPLC.

Abstract

A process for the preparation of taxol and derivatives of taxol (I) is disclosed. The process involves reacting a β-alkoxycarbonylamino-phenylpropionic acid with a 13-hydroxy taxane to produce an ester of the taxane at C-13; and then deprotecting the β-alkoxycarbonylamino-phenylpropionic ester to produce a β-amino-α-hydroxybenzenepropanoic ester of the taxane. Intermediates useful in the process are also disclosed.

Description

PROCESS FOR PRODUCING TAXOL DERIVATIVES AND INTERMEDIATES THEREFOR
Field of the Invention
The invention relates to a process for the
preparation of taxol I and derivatives of taxol
Figure imgf000003_0001
and to intermediates useful in the process.
Background of the Invention
Taxol (I) is currently in clinical trials and has demonstrated efficacy with manageable side
effects in 30 to 35% of cases of ovarian cancer and 56% of cases of metastatic breast cancer, but large scale clinical trials have been hampered by the small available supplies of the drug.
Taxol, whose generic name as a drug is
paclitaxel, is currently produced by extraction from the bark of the Pacific yew, Taxus brevifolia . The Pacific yew is a slow growing conifer found in the understory of old growth stands in the Pacific
Northwest. Ten thousand kilograms of bark are required to produce one kilogram of taxol, which is enough to treat only 500 patients. For this reason the chemical synthesis of taxol has aroused great interest. However, the sterically crowded,
chemically sensitive and chirally complex taxane ring structure
Figure imgf000004_0001
has essentially forestalled any practical synthesis de novo. As a result, current chemical efforts are focused on semisynthesis from more readily available congeners. The chemistry of taxol and related diterpenoids has been described in two excellent recent review articles [Kingston, Pharm. Ther. 52, 1- 34 (1991) and Nicolaou et al . Angew. Chem. Int . Ed. 33., 15-44 (1994)].
Although no good source of taxol has been found, a related compound baccatin III,
Figure imgf000005_0001
wherein R is hydrogen, is much more readily available from the needles of the European yew, Taxus baccata . This has led to a very active exploration of semi-synthetic routes from baccatin to taxol. The most practical present routes of semi-synthesis involve the attachment of the side chain of taxol
Figure imgf000005_0002
onto a suitably protected baccatin, followed by deprotection.
Several of the known routes for the semi-synthesis of taxol proceed through a substantially optically pure azido ester of the formula V:
Figure imgf000006_0001
The azide is reduced, resulting in a trans-acylation from oxygen to nitrogen;
Figure imgf000006_0002
the hydroxyl of the resulting β-amido ester VII
Figure imgf000006_0003
is protected; and the ester is saponified to produce the protected carboxylic acid VIII:
Figure imgf000007_0001
This protected acid is then coupled with the suitably protected taxane ring system. Consistent with common usage, the term "taxane" is understood to encompass diterpenoids having a 6, 10-methanobenzocyclodecane ring structure oxygenated at least at the 3,5,8,11 and 12 positions and carbon-substituted at
4, 6, 9, 12a, 13 and 13. In the case of taxanes of present therapeutic interest (having the baccatin and taxol ring structures), the oxygen at position 8 of the methanobenzocyclodecane is an alcohol (which will be esterified) and the carbon at 4 and the oxygen at 3 are cyclized to form an oxetane ring. Structure II above reflects the pattern of substitution of the taxanes of interest and shows the numbering system commonly used for taxol, which is different from the numbering system of the parent
methanobenzocyclodecane.
Summary of the Invention The process of the invention shown in Scheme A provides an improved synthesis of taxol and related structures by the coupling of an optically pure β-protected amino carboxylic acid (IX) with the
suitably protected taxane ring structure X in which R2 is a protecting group for an alcohol (see below):
Figure imgf000008_0001
The amino protecting group is then removed to
liberate the free amine, which undergoes internal transacylation to produce the desired o;-hydroxyl β-amido sidechain in the taxol.
In one aspect, the invention relates to a process for the preparation of taxol, and derivatives thereof, comprising: (a) reacting a β-alkoxycarbonyl-aminophenylpropionic acid of formula (XII) wherein R1 is C1 to C10 alkyl, phenyl or substituted phenyl; R3 is hydrogen, loweralkyl, loweralkoxyl, di- loweralkylamino or halo; and R4 is benzyl (Cbz), t-butyl (tBoc), allyl (Aloe), trichloroethyl (Troc), or 9-fluorenylmethyl (Fmoc), with a 13-hydroxy taxane to produce an amidophenylpropionic ester at C-13 of the taxane;
Figure imgf000009_0001
and (b) removing the β-amino protecting group by treatment with an acid or by reduction followed by internal acyl transfer to produce a β-amido-α-hydroxyphenylpropionic ester of the taxane.
Preferred R1 substituents are phenyl, substituted phenyl (particularly 4-chlorophenyl) or t-butoxyl; the preferred R3 is hydrogen. The term "alkyl" as used herein refers to saturated hydrocarbons,
including straight and branched chains as well as cyclic structures such as cyclohexyl. Lower alkyl refers to alkyl of six or fewer carbons. The
definitions of substituents are presented herein in their first occurrence and retain that definition throughout the text.
In a more specific embodiment, the process of the invention relates to a process as above
comprising (a) reacting a β-alkoxycarbonylamino-phenylpropionic acid of formula (IX), wherein R4 is t-butyl, benzyl or 9-fluorenylmethyl,
Figure imgf000010_0001
with a taxane of formula (X)
Figure imgf000010_0002
to produce an alkoxycarbonylaminophenylpropionic ester at C-13 of formula (XI)
Figure imgf000011_0001
and (b) removing the alkoxycarbonyl protecting group of the phenylpropionic ester of taxane to produce a β-amido-α-hydroxyphenylpropionic ester of taxane of formula XIII:
Figure imgf000011_0002
X wherein R2 is a protecting group for an alcohol. The term "protecting group for an alcohol" refers to a residue that is stable under the conditions of the condensation of the benzenepropanoic acid with the 13-hydroxy taxane, but that can be cleaved to an alcohol under conditions that do not otherwise affect the β-amido-α-hydroxybenzenepropanoic ester of the taxane. Suitable protecting groups include 1,1,1-trichloroethoxycarbonyl (Troc), removable by zinc in acetic acid and aryldialkylsilanes or trialklsilanes, removable by mild acid such as 0.5% HCl in methanol. A preferred protecting group for the C-7 hydroxyl is trihexylsilyl .
The process of the invention may further
comprise the additional step of cleaving the
protecting group R2 to produce taxol, and the step of deprotecting the β-aminobenzenepropanoic ester may also cleave the protecting group R2, whereby a 2',7-dihydroxy-3' -amidoester is produced in a single reaction.
In a further aspect, the invention relates to compounds of formula XIV:
Figure imgf000012_0001
wherein R1 is C1 to C10 alkyl, C1 to C10 alkoxyl, phenyl or substituted phenyl; R3 is hydrogen, loweralkyl, loweralkoxyl, di-loweralkylamino or halo and R4 is allyl, benzyl, t-butyl, or 9-fluorenylmethyl. The compounds are novel and are useful for preparing taxol according to the method of the invention.
Preferred compounds are those in which R1 is phenyl, t-butoxyl or 4-chlorophenyl and R3 is hydrogen.
In a further embodiment, the invention relates to compounds of formula XV
Figure imgf000013_0001
wherein R2 is trialkylsilyl (e.g. t-butyldimethylsilyl, trihexylsilyl, triethylsilyl or trimethylsilyl), or aryldialkylsilyl (e.g.
phenyldimethylsilyl) and the other substituents are as defined before. The compounds are useful as intermediates in the process of the invention.
Detailed Description of the Invention The central process of the invention involves the reaction of a suitably protected 13-hydroxy-taxane X with a β-alkoxycarbonylamino-phenylpropionic acid XIV to form the ester XV. In a second step the amine is deprotected by procedures known in the art, such as hydrogenation in the presence of a catalyst (for R4 = benzyl) or treatment with mild acid (for R4 = t-butyl), whereupon the acyl group is transferred from the α-oxygen to the newly created β-amino function. The C-7 hydroxyl of baccatin is the most reactive hydroxyl and must commonly be protected during the reaction to form the ester. It will then be deprotected in a final step to produce taxol or a taxol analog. The reaction is shown below in Scheme B, which is a generic version of Scheme A:
Figure imgf000015_0001
The process of the invention is distinguished from processes of the art (shown in Scheme C) in which an α-hydroxyl-protected β-amidobenzenepropanoic acid XVII
Figure imgf000017_0001
is reacted with the suitably protected taxane X and the protecting group R4 is subsequently removed from the α-hydroxyl.
The optically pure β-alkoxycarbonylaminophenyl-propionic acid XIV
Figure imgf000018_0001
may be prepared by a number of possible routes. In one synthetic route (Scheme D),
Figure imgf000018_0002
readily available optically pure (2R, 3S)-phenylisoserine is treated with an alkyl
chloroformate or equivalent such as di-t-butyl dicarbonate [(Boc)2O] under Schotten-Baumann
conditions (aq. NaOH or K2CO3) to give the β-alkoxycarbonylamino-α-hydroxyl acid. The α-hydroxyl of the acid is then reacted with an acid chloride such as benzoyl chloride in the presence of a base such as aqueous NaOH to give the desired β-alkoxycarbonylamino-phenylpropionic acid after neutralization and purification. Alternatively, as shown in Scheme E, the β-alkoxycarbonyl-aminophenylpropionic acid can be synthesized from optically pure ethyl (2R,3S)-phenylglycidate, which is obtained by enzymatic resolution of the racemic glycidate according to the method of U.S. patent 5,274,300 or from ethyl
(2R, 3S) -2, 3-dihydroxy-3-phenylpropionate according to the procedure of Kolb et al [Tetrahedron 48, 10515 (1992)]. The ethyl (2R, 3S) -phenylglycidate is then converted to the trimethylsilylethyl ester by
treatment with 2-trimethylsilylethanol in the
presence of a base such as 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU). The resulting epoxide is opened with a source of Br-, such as lithium bromide in acetic acid/THF or diethylamine hydrobromide, in the presence of an aluminum
compound, such as diethylaluminum chloride, to produce (2R,3R) -3-bromo-2-hydroxy-3-phenylpropionate XXIII, which is then treated with sodium azide in DMF to produce the β-azidopropionate. The 3-azido-2-hydroxy ester is then reduced to the β-amino ester which is then treated with an alkyl chloroformate (R4OCOCl) followed by an acid chloride (R1COCl), such as benzoyl chloride, to produce the appropriate 3-alkoxycarbonylamino-2-acyloxyphenylpropionate ester.
Figure imgf000020_0001
Alternatively, the 3-azido-2-hydroxy ester is treated with an acid chloride (R1COCl), such as benzoyl chloride, to give the 3-azido-2-acyloxy ester which is then hydrogenated in the presence of di-alkyl-dicarbonate, such as Boc2O, under 1 atm of hydrogen over a catalyst, such as Pd/C, to give the 3-alkoxycarbonylamino-2-acyloxyphenylpropionic ester. The trimethylsilylethyl ester is then treated with tetrabutylammonium fluoride in THF to give the 3-alkoxycarbonylamino-2-acyloxyphenylpropionic acid after acidification.
Alternative syntheses of various of the
intermediates in the synthesis of the β-azido
benzenepropanoic acid have been published by Gou et al. [J. Org. Chem. 58, 1287-1289 (1993)], Bajwa et al. [Tetrahedron Letters 32, 3021-3024 (1991)] and Bonini et al. [J. Chem. Soc. Chem. Commun. (1994) 2767-2768], and the reader is directed to those references for details. The condensation of the β-alkoxycarbonyl- aminophenylpropionic acid with a suitably protected baccatin can be carried out using standard ester formation methods. Preferably, the condensation of the baccatin with the acid sidechain is performed using at least one equivalent of the acid in the presence of at least one equivalent of activating reagent such as dialkylcarbodiimide, di-2-pyridylcarbonate and PhOPOCl2 or Me2NPOCl2 and a base such as 4-dimethylaminopyridine (DMAP) or 4-pyrrolidinopyridine (4-PP) in an inert solvent. Most preferably, the condensation is performed using 1.2- 1.5 equivalents of the acid XIV in the presence of 1.2-1.5 equivalents of DCC or DIC and 0.2-0.5 equivalents of DMAP or 4-PP in toluene at 40-50°C for 4-10 hours. When R4 of the alkoxycarbonylaminophenylpropionic acid is t-butyl and R2 of the 7-hydroxyl protecting group is a silyl group, the conversion of the
condensation product to taxol and analogs is most conveniently accomplished in acidic medium such as trifluroacetic acid (TFA) in methylene dichloride or THF or in neat formic acid. When R4 is benzyl, allyl, or 9-fluorenylmethyl and R2 is silyl, the conversion is accomplished by removal of the silyl group with an acid, as above, or with HF/pyridine or with
tetrabutylammonium fluoride in THF followed by
catalytic hydrogenation using Pd/C or Pd(PPh3)4 and hydrogen or a hydrogen donor such as ammonium
formate. When R4 is trichloroethyl and R2 is
trichloroethoxycarbonyl, the conversion is
accomplished by reduction with zinc in HOAc. Under these conditions, the taxol is recovered by
neutralization with an aqueous solution of sodium bicarbonate in an inert solvent such as ethyl
acetate, toluene or methylene dichloride, followed by purification by crystallization or chromatography on silica gel.
Several possible alcohol protecting groups R2 for the C-7 hydroxyl were compared as to ease of
protection and deprotection, stability of the product towards further reaction conditions, selectivity of the reaction for the protection of the desired functional group over other hydroxyl groups in the molecule, ease of purification and cost of the materials. As a part of the exploration of R2 groups, the acetylation of the C-10 hydroxyl group was also studied, and the results of this study are presented in the experimental section below.
10-Deacetyl baccatin-III (10-DAB) was treated with a variety of reagents under a number of reaction conditions. It appears that silyl protecting groups were more well behaved than other common protecting groups. Treatment of 10-DAB with triethylsilyl chloride and imidazole in DMF resulted in the smooth preparation of the triethyl silyl ether in 70% yield. Under similar conditions, treatment with t-butylmethoxphenylsilyl bromide resulted in the silylated taxoid in a yield of 89%. The
phenyldimethyl silyl derivative was prepared in an acceptable yield of 74%. A preferred protecting group is tri-n-hexylsilyl. When treated with tri-n-hexylsilyl chloride, 10-DAB underwent smooth silylation to produce the C-7 silylated material in 80% yield.
Very importantly, the pure tri-n-hexylsilyl ether product is obtained by recrystallization. No
chromatography is necessary.
Acetylation at C-10 of the C-7 silylated
substrates was accomplished by treatment with acetyl chloride in pyridine at 0°C. Acetylation of both the triethylsilyl and tri-n-hexylsilyl ethers proceeded to give the desired acylation at the C-10 hydroxyl group. Although in both cases some desilylation occurred, it is postulated that this side reaction, which is probably induced by hydrochloric acid generated during the reaction, may be suppressed by modification of the existing conditions or by
acylation of the discrete alkoxide. The more labile phenyldimethylsilyl group is cleaved to a greater extent than the trialkylsilyl ethers under the same reaction conditions. The unoptimized yield for the acylation of the tri-n-hexylsilyl derivative is 70%. The removal of the C-7 silyl protecting group may be accomplished by HF in pyridine, resulting in clean conversion to the free alcohol. Cleavage of the tri-n-hexylsilyl ether was slower than the triethylsilyl ether; the yield for the tri-n-hexylsilyl ether deprotection was 68%. In the case of the 7-TES derivative, HF in acetonitrile proved too harsh and resulted in the production of a complex mixture of products.
The presently preferred candidate for C-7 hydroxyl protection is the tri-n-hexylsilyl ether. Tri-n-hexylsilyl chloride has similar reactivity to triethylsilyl chloride and is cheaper than
triethylsilyl chloride; the intermediate ether can be purified by recrystallization; and the protecting group can be cleanly cleaved.
Although the synthesis has been illustrated with compounds in which R1 is phenyl and R3 is hydrogen, the person of skill will readily appreciate that analogous reactions could be carried out employing starting materials and intermediates in which R1 is other than phenyl and R3 is other than hydrogen. Examples:
Example-1:
(2R, 3S) -phenylisoserine hydrochloride (6.0 g, 27.6 mmol) was dissolved in H2O/tBuOH (50 mlL each) at room temperature. A solution of NaOH (50% aq., 4.6 g, 58 mmol) was added followed by di-t-butyl dicarbonate (7.23 g, 33.1 mmol). The resulting mixture was stirred at. room temperature overnight and
concentrated to ca. 30 mL. The residue was diluted with EtOAc (150 mL) and acidified with 1 N H2SO4 to pH 3-4. The aq. phase was separated and extracted with 50 mL of ethyl acetate (EtOAc). The combined organic phase was washed with sat'd NaCl and dried over
Na2SO4. After filtration and concentration, the resulting yellow solid was recrystallized from
EtOAc/heptane to give (2R, 3S) -3-t-butyloxycarbonyl-amino-2-hydroxyphenylpropionic acid as a white solid (5.9 g, 75.6% yield).
Example-2:
(2R,3S) -3-t-butyloxycarbonylamino-2-hydroxyphenyl-propionic acid (1.41 g, 5 mmol) was dissolved in H2O/acetone (10 mL each) containing 0.4 g of 50% aq. NaOH (5 mmol). The solution was cooled with ice water. Benzoyl chloride (1.2 mL, 10 mmol) and 1 N NaOH solution were added alternatively in small portions while maintaining the pH at ca. 10-11. After addition, the mixture was stirred at room temperature for 2 h at pH 9-11. The mixture was then diluted with EtOAc (100 mL) and acidified with 1 N H2SO4 to pH 2-3. The aq. phase was separated and extracted with 30 mL of EtOAc. The combined organic phase was washed with sat'd NaCl and dried over Na2SO4. The crude product was then purified on silica gel eluting with EtOAc/hexane and EtOAc to give (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid as a white solid (0.96 g, 50 % yield).
Example-3:
Ethyl (2R,3S) -phenylglycidate (36 g, 0.19 mol) was treated with 2-trimethylsilylethanol (67 g, 0.57 mol) in toluene (100 mL) in the presence of catalytic amount of -DBU at 60-80 C for 2-3 days. The reaction was then concentrated under vacuum to give the crude trimethylsilyl ethyl ester (ca. 50 g). The crude ester was dissolved in THF (150 mL) and cooled with icewater. Acetic acid (44 mL, 0.8 mol) was added followed by LiBr (49 g, 0.56 mol) in three portions. The mixture was stirred from 5 C to room temperature for 26 h and was concentrated to dryness to remove THF. The residue was diluted with 100 mL of H2O and extracted with 2×300 mL of methyl t-butyl ether
(MTBE). The MTBE extracts were then washed with water (50 mL) and sat'd NaCl and concentrated to give a crude oil which was purified on silica gel eluting with hexane and 10% EtOAc in hexane to give a white solid (12.4 g, 19% yield) as the (2R, 3R) -3-bromo-2-hydroxyphenylpropionic acid 2-trimethylsilylethyl ester. Example-4:
The ester from Example-3 (12.3 g, 35.6 mmol) was treated with NaN3 (7.0 g, 0.11 mol) in 40 mL of DMF at 60-70 C for 18 h. The mixture was cooled and diluted with 50 mL of water and extracted with 300 mL of MTBE. The MTBE solution was washed with water (40 mL) and sat'd NaCl (30 mL) and concentrated to give a crude oil which was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give (2R,3S)-3- azido-2-hydroxyphenylpropionic acid 2-trimethylsilyl-ethyl ester (11.0 g, 100% yield).
Example-5:
The azido ester from Example-4 (11.0 g, 35.6 mmol) was hydrogenated on a Parr-shaker at 50 psi in ethanol (EtOH) in the presence of catalytic amount of Pd/C (2.0 g). After removal of the catalyst and concentration, the resulting 3-amino-2-hydroxyphenylpropionic ester was dissolved in
tetrahydrofuran (THF) (50 mL) and treated with di-t-butyl dicarbonate (9.3 g, 42.7 mmol) and Et3N (7.2 g, 71.2 mmol) at room temperature overnight. The mixture was concentrated and diluted with MTBE (250 mL) and washed with water and brine. After drying and
concentration, the residue was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give (2R, 3S) -3-t-butyloxycarbonylamino-2-hydroxyphenylpropionic acid 2-trimethylsilylethyl ester (12.0 g, 90% yield). Example-6:
The ester (12 g, 31.5 mmol) from example-5 was dissolved in THF (50 mL) and cooled with icewater. Et3N (6.4 g, 63 mmol) was added, followed by benzoyl chloride (5.3 g, 38 mmol) dropwise with cooling. The resulting mixture was stirred at room temperature overnight and diluted with EtOAc (250 mL) and quenched with 50 mL of water. The aq. phase was separated and the organic phase was washed with dilute H2SO4, water and then sat'd aq. NaHCO3. After drying, the crude product was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give (2R, 3S) -3-t-butyloxycarbonylamino-2- benzoyloxyphenylpropionic acid 2-trimethylsilylethyl ester (13.8 g, 90% yield).
Example-7:
The ester (13.8 g, 28.4 mmol) from Example-6 was dissolved in THF (50 mL) and cooled with icewater.
Tetrabutylammonium fluoride in THF (1.0 M in THF, 57 mL) was added dropwise. The resulting solution was stirred at. room temperature for 7 h and concentrated to dryness. The residue was dissolved in 300 mL of EtOAc and acidified with 1 N H2SO4 to pH 3-4. The
EtOAc solution was then washed with water (20 mL) and sat'd NaCl (20 mL) and concentrated to dryness. The crude product was purified on silica gel eluting with EtOAc to give (2R, 3S) -3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid as a white solid (8.7 g, 80% yield).
Example-8:
The 3-azido-2-hydroxy ester from Example-4 (11.0 g, 35.6 mmol) was dissolved 100 mL of EtOAc and 50 mL of THF. Triethylamine (10 mL, 71.2 mmol) was added and the solution was cooled with icewater. Benzoyl chloride (4.2 mL, 36 mmol) was added and the mixture was stirred at room temperature for 20 h. The mixture was quenched with 50 mL of water and diluted with 150 mL of EtOAc. The organic phase was separated and washed with dilute H2SO4, water and sat'd NaCl and concentrated. The residue was then purified on silica gel eluting with hexane and 7% EtOA/hexane to give 3-azido-2-benzoyloxyphenylpropionic acid 2- trimethylsilylethyl ester as a pale yellow oil (10.6 g, 72% yield). Example- 9 :
The 3-azido-2-benzoyloxy ester from Example-8 (2.06 g, 5 mmol) was dissolved in EtOAc (20 mL) and di-t-butyl-dicarbonate (2.2 g, 10 mmol) and 0.2 g of 10% Pd/C were added. The mixture was hydrogenated at 1 atm with stirring at room temperature for 4 days and then filtered. The filtrate was concentrated to give a residue which was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give 3-t-butyloxycarbonylamino-2 -benzoyloxyphenylpropionic acid 2-trimethylsilylethyl ester as a glassy solid (2.0 g, 84% yield).
Example-10:
The ester from Example-9 (2.0 g, 4.22 mmol) was dissolved in 20 mL of THF and nBu4NF in THF (1.0 M,
8.5 mL, 8.5 mmol) was added. The solution was stirred at room temperature for 3 h and concentrated to dryness. The residue was dissolved in EtOAc (150 mL) and acidified with dilute H2SO4 to pH 3-4. The organic phase was then washed with sat'd NaCl and
concentrated. The residue was purified on silica gel eluting with EtOAc to give a white solid as (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid (1.28g, 78.5% yield). Example-11:
10-Deacetylbaccatin III (1 g, 1.8 mmol) and
imidazole, (980 mg. 14.4 mmol) were dissolved in 60 mL dry DMF under an atmosphere of argon in a 200 mL roundbottom flask equipped with a stirring bar. Tri- n-hexylsilyl chloride (4 mL, 10.3 mmol) was added and the mixture was stirred for 6 h at room temperature. Ethyl acetate and water were added and the phases allowed to separate. The organic layer was separated and the aqueous phase was washed with brine and dried over anhydrous MgSO4. After filtration and
evaporation of the solvent under reduced pressure, the crude product was recrystallized from methylene chloride and hexanes to yield 1.11g of the pure product (74% yield) : mp. 203°C.
Example-12.
7-Tri-n-hexylsilyl-10-deacetylbaccatin III (250 mg. 0.3 mmol) from example 11 was dissolved in 7.7 mL of anhydrous pyridine under an argon atmosphere in a 25 mL roundbottom flask equipped with a stirring bar. The solution was cooled to 0°C and acetyl chloride (100μL, 1.5 mmol) was added dropwise. The mixture was stirred for 20 h at 0°C. A further 100 μL of acetyl chloride was added and the mixture stirred for another 20 h at 0°C. Ethyl acetate was added, followed by water at 0°C. The organic phase was removed and the aqueous phase was extracted twice with ethyl acetate. The organic layers were combined and washed with saturated CuSO4 solution, (until the pyridine had been completely removed), water and brine and finally dried over anhydrous MgSO4. After filtration, and removal of the solvent under reduced pressure, the resulting residue was purified by flash chromatography on silica gel (elution with 30-50% ethyl acetate/hexanes) to yield 171 mg of pure product (66% yield).
Example-13
7-Tri-n-hexylsilylbaccatin III (250 mg, 0.3 mmol) from example 12 was dissolved in 15 mL of anhydrous THF under an atmosphere of argon in a 50 mL roundbottom flask equipped with a stirring bar. HF- pyridine (3 mL) was then added dropwise. The
reaction mixture was stirred for 2 h at 25°C. Ethyl acetate and water were added. After separation of the phases, the aqueous phase was extracted twice with ethyl acetate. The combined organic extracts were washed with saturated copper sulphate, water and brine, and dried over anhydrous magnesium sulphate. After filtration and removal of the solvent under reduced pressure, the residue was purified by flash chromatography on silica gel (elution with 70-100% ethyl acetate/hexanes) to yield 111 mg of pure baccatin III (68% yield).
Example-14
A mixture of (2R, 3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid (78 mg, 0.2 mmol)
(Example 10), dicyclohexylcarbodiimide (DCC) (41 mg, 0.2 mmol), 4 -pyrrolidinopyridine (15 mg, 0.1 mmol) and 7- triethylsilyl baccatin (TES-baccatin) (70 mg, 0.1 mmol) in 0.3 mL of dry toluene was heated at 50 C for 6 h. The mixture was then concentrated and purified on silica gel eluting with hexane and 30% EtOAc/hexane to give the (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid ester of 7-TES-baccatin at the C-13 hydroxyl group as a white solid (100 mg, 93% yield).
Example-15:
A mixture of (2R, 3S)-3-t-butyloxycarbonylamino-2- benzoyloxyphenylpropionic acid (78 mg, 0.2 mmol), diisopropylcarbodiimide (DIC) (38 mg, 0.3 mmol), 4- pyrrolidinopyridine (15 mg, 0.1 mmol) and 7-TES- baccatin (94mg, 0.134 mmol) in 0.5 mL of dry toluene was heated at 50 C for 6.5 h. The solution was then cooled and diluted with EtOAc/toluene and washed with water, dilute H2SO4 and sat'd NaCl. The solution was concentrated to dryness to give crude (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid ester of 7-TES-baccatin (200 mg).
Example-16:
As an alternative to example 5, the (2R, 3S)-3-azido-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester from. Example-4 (6.2 g, 20.2 mmol) was treated with ammonium formate (5 g, 80 mmol) in the presence of 10% Pd/C (0.6 g) in 50 mL of methanol for 3-5 hours. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated to dryness. The residue was diluted with 150 mL of ethyl acetate and washed with water and sodium bicarbonate solution. After concentration, the crude product was purified on silica gel eluting with ethyl acetate and 10% methanol in ethyl acetate to give pure (2R, 3S)-3-amino-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester as a yellow sticky oil (4.0 g, 70% yield).
Example-17:
The amino alcohol from Example-16 (2.2 g, 7.8 mmol) and Et3N (2.2 mL, 15.6 mmol) were dissolved in 10 mL of THF and cooled with ice water. Benzyl
chloroformate (Cbz-Cl) (1.4 mL, 9.36 mmol) was added dropwise to the solution. The resulting white slurry was stirred at room temperature for 2 h. The
reaction mixture was diluted with 150 mL of ethyl acetate and washed with water, dilute sulfuric acid and sat'd NaCl solution. The crude product was then purified on silica gel eluting with hexane and 10% ethyl acetate in hexane to give the (2R,3S)-3- benzyloxycarbonylamino-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.33 g, 41% yield).
Example-18:
The (2R,3S) -3-benzyloxycarbonylamino-2-hydroxyphenylpropionic acid, 2-trimethyleilylethyl ester (1.33 g, 3.2 mmol) from Example-17 and
triethylamine (0.9 mL, 6.4 mmol) were dissolved in 10 mL of THF and cooled with ice water. Benzoyl
chloride (0.41 mL, 3.53 mmol) was added dropwise.
The mixture was stirred at room temperature overnight and worked up and purified as in Example-14 to give the (2R,3S)-3-benzyloxycarbonylamino-2-benzoyloxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.1g).
Example-19:
The (2R,3S) -3-benzyloxycarbonylamino-2-benzoyloxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.1 g) from Example-18 was dissolved in 5 mL of THF and cooled with ice water. A solution of Bu4NF in THF (1.0 M, 6mL) was added. The solution was stirred at room temperature for 2-4 h and
concentrated to dryness. The residue was dissolved in 100 mL of ethyl acetate and acetified with dilute sulfuric acid and washed with water and sat'd NaCl. After concentration and drying, the (2R,3S)-3-benzyloxycarbonylamino-2-benzoyloxyphenylpropionic acid was obtained as a white foamy solid (0.86 g).
Example-20:
A mixture of (2R, 3S)-3-benzyloxycarbonylamino-2- benzoyloxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.1 g) (126 mg, 0.3 mmol), 4- pyrrolidinopyridine (22 mg, 0.15 mmol), DCC (68 mg, 0.32 mmol) and 7-TES-baccatin (70 mg, 0.1 mmol) in 0.4 mL of dry toluene was heated at 50 C for 7 h.
The reaction mixture was then cooled and purified on silica gel eluting with hexane and 15% ethyl
acetate/hexane to give the (2R,3S)-3-benzylcarbonylamino-2-benzoyloxyphenylpropionic acid, 7-TES-baccatin ester (108 mg).
Example-21:
The 7-TES-baccatin ester from Example-20 (50 mg), ammonium formate (0.5 g) and 10% Pd/C (10 mg) were dissolved in methanol (2 mL) and stirred at room temperature for 4-5 h. The catalyst was removed by filtration and the filtrate was concentrated to dryness. The residue was then dissolved in 1 mL of formic acid and stirred at room temperature
overnight. The solution was concentrated to dryness and the crude product was purified on silica gel eluting with ethyl acetate to give Taxol (9 mg) identical with natural taxol by HNMR and HPLC.

Claims

1. A process for the preparation of taxol and derivatives thereof comprising
(a) reacting a β- alkoxycarbonylaminophenylpropionic acid of formula
Figure imgf000035_0001
wherein R1 is C1 to C10 alkyl, C1 to C10 alkoxyl, phenyl or substituted phenyl; R3 is hydrogen, loweralkyl, loweralkoxyl, di-loweralkylamino or halo; and R4 is benzyl, t-butyl, allyl,
trichloroethyl, or 9-fluorenylmethyl, with a 13- hydroxy taxane to produce a β- alkoxycarbonylaminophenylpropionic ester of said taxane at C-13; and
(b) cleaving the β-alkoxycarbonyl from said β-alkoxycarbonylaminophenylpropionic ester of taxane to produce a β-amido-α- hydroxybenzenepropanoic ester of said taxane.
2. A process according to claim 1 wherein R1 is phenyl, t-butoxyl or 4-chlorophenyl and R3 is
hydrogen.
3. A process according to claim 1 comprising
(a) reacting a β-alkoxycarbonyl- aminophenylpropionic acid of formula
Figure imgf000036_0001
with a taxane of formula
Figure imgf000036_0002
to produce an β-alkoxycarbonylaminophenylpropionic ester at C-13 of taxane of formula
Figure imgf000036_0003
and
(b) cleaving the β-alkoxycarbonyl of said β-alkoxycarbonylaminophenylpropionic ester of taxane to produce a β-amido-α- hydroxybenzenepropanoic ester of said taxane of formula
Figure imgf000037_0001
wherein R2 is a protecting group for an alcohol.
4. A process according to claim 3 wherein said protecting group for an alcohol is 1,1,1-trichloroethoxycarbonyl, trialkylsilyl or
aryldialkylsilyl.
5. A process according to claim 4 wherein said protecting group for an alcohol is tri-n-hexylsilyl.
6. A process according to claim 3 comprising the additional step of cleaving said protecting group for an alcohol to produce taxol.
7. A process according to claim 3 wherein said step of cleaving the β-alkoxycarbonyl of said β-alkoxycarbonylaminophenylpropionic ester also cleaves said protecting group for said alcohol, whereby a 2', 7-dihydroxy-3'-amidoester is produced in a single reaction.
A compound of formula
Figure imgf000038_0001
wherein R1 is C1 to C10 alkyl, C1 to C10 alkoxyl, phenyl or substituted phenyl; R3 is hydrogen, loweralkyl, loweralkoxyl, di-loweralkylamino or halo; and R4 is benzyl, t-butyl, allyl, trichloroethyl, or 9-fluorenylmethyl.
9. A compound according to claim 8 wherein R1 is phenyl, t-butoxyl or 4-chlorophenyl and R3 is hydrogen.
10. A compound of formula
Figure imgf000039_0001
wherein R1 is C1 to C10 alkyl, C1 to C10 alkoxyl, phenyl or substituted phenyl; R2 is 1,1,1-trichloroethoxycarbonyl, trialkylsilyl or
aryldialkylsilyl; R3 is hydrogen, loweralkyl,
loweralkoxyl, di-loweralkylamino or halo and R4 is benzyl, t-butyl, allyl, trichloroethyl, or 9-fluorenylmethyl.
11. A compound of formula
Figure imgf000039_0002
according to claim 10
12. A compound according to claim 11 wherein R2 is trihexylsilyl and R4 is t-butyl.
PCT/US1996/012666 1995-08-11 1996-08-02 Process for producing taxol derivatives and intermediates therefor WO1997007110A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU66464/96A AU6646496A (en) 1995-08-11 1996-08-02 Process for producing taxol derivatives and intermediates therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US214095P 1995-08-11 1995-08-11
US60/002,140 1995-08-11
US08/589,142 US5760251A (en) 1995-08-11 1996-01-19 Taxol process and compounds
US08/589,142 1996-01-19

Publications (1)

Publication Number Publication Date
WO1997007110A1 true WO1997007110A1 (en) 1997-02-27

Family

ID=26670002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012666 WO1997007110A1 (en) 1995-08-11 1996-08-02 Process for producing taxol derivatives and intermediates therefor

Country Status (3)

Country Link
US (1) US5760251A (en)
AU (1) AU6646496A (en)
WO (1) WO1997007110A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191287B1 (en) 1997-08-18 2001-02-20 Florida State University Process for selective derivatization of taxanes
WO2006135656A2 (en) * 2005-06-10 2006-12-21 Florida State University Research Foundation, Inc. Processes for the preparation of paclitaxel
US7220872B2 (en) * 2002-04-05 2007-05-22 Natural Pharmaceuticals, Inc. Conversion of taxane molecules
US7589111B2 (en) 2004-02-13 2009-09-15 Florida State University Research Foundation, Inc. C10 cyclopentyl ester substituted taxanes
US7667055B2 (en) 2005-06-10 2010-02-23 Florida State University Research Foundation, Inc. Processes for the production of polycyclic fused ring compounds
US8242166B2 (en) 2008-03-31 2012-08-14 Florida State University Research Foundation, Inc. C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes
WO2012117417A1 (en) * 2011-02-28 2012-09-07 Shilpa Medicare Limited Process for preparing (2r, 3s) 2-benzyloxy-3-tert-butoxy carbonyl amino-3-phenyl propionic acid
CN103086924A (en) * 2013-01-17 2013-05-08 暨明医药科技(苏州)有限公司 Synthetic method of docetaxel and intermediate of docetaxel
WO2016140104A1 (en) * 2015-03-03 2016-09-09 東レ・ファインケミカル株式会社 3-phenylisoserine derivative production method

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6452024B1 (en) 2000-02-22 2002-09-17 Chaichem Pharmaceuticals International Process for extraction and purification of paclitaxel from natural sources
US6759539B1 (en) 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
CN112661727B (en) * 2020-12-29 2023-09-26 重庆市碚圣医药科技股份有限公司 Purification method of 7- (2, 2-trichloroethyl oxycarbonyl) taxol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253739A1 (en) * 1986-07-17 1988-01-20 Rhone-Poulenc Sante Process for the preparation of taxol and of desacetyl-10-taxol
EP0336840A1 (en) * 1988-04-06 1989-10-11 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of taxol
EP0336841A1 (en) * 1988-04-06 1989-10-11 Rhone-Poulenc Sante Process for the preparation of baccatin III derivatives and of desacetyl-10 baccatin III
WO1993018210A1 (en) * 1992-03-13 1993-09-16 Rhone-Poulenc Rorer S.A. Process for the preparation of taxane derivatives
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
EP0569281A1 (en) * 1992-05-06 1993-11-10 Bristol-Myers Squibb Company Benzoate derivatives of taxol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE34277E (en) * 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
US5274300A (en) * 1988-10-26 1993-12-28 Sepracor, Inc. Enzymatic hydrolysis of glycidate esters in the presence of bisulfite anion
US5175315A (en) * 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
FR2702212B1 (en) * 1993-03-02 1995-04-07 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253739A1 (en) * 1986-07-17 1988-01-20 Rhone-Poulenc Sante Process for the preparation of taxol and of desacetyl-10-taxol
EP0336840A1 (en) * 1988-04-06 1989-10-11 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of taxol
EP0336841A1 (en) * 1988-04-06 1989-10-11 Rhone-Poulenc Sante Process for the preparation of baccatin III derivatives and of desacetyl-10 baccatin III
WO1993018210A1 (en) * 1992-03-13 1993-09-16 Rhone-Poulenc Rorer S.A. Process for the preparation of taxane derivatives
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
EP0569281A1 (en) * 1992-05-06 1993-11-10 Bristol-Myers Squibb Company Benzoate derivatives of taxol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONDONI ET AL: "Thiazolyl alpha-Amino Ketones", SYNTHESIS, vol. 11, 1993, pages 1162 - 1176, XP002017074 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191287B1 (en) 1997-08-18 2001-02-20 Florida State University Process for selective derivatization of taxanes
US6291691B1 (en) 1997-08-18 2001-09-18 Florida State University Process for selective derivatization of taxanes
US6706896B1 (en) 1997-08-18 2004-03-16 Florida State University Process for selective derivatization of taxanes
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US7220872B2 (en) * 2002-04-05 2007-05-22 Natural Pharmaceuticals, Inc. Conversion of taxane molecules
US8003812B2 (en) 2004-02-13 2011-08-23 Florida State University Research Foundation, Inc. C10 cyclopentyl ester substituted taxanes
US7589111B2 (en) 2004-02-13 2009-09-15 Florida State University Research Foundation, Inc. C10 cyclopentyl ester substituted taxanes
US7550608B2 (en) 2005-06-10 2009-06-23 Florida State University Research Foundation, Inc. Processes for the preparation of docetaxel
US7358378B2 (en) 2005-06-10 2008-04-15 Florida State University Research Foundation, Inc. Processes for the preparation of paclitaxel
WO2006135656A3 (en) * 2005-06-10 2007-06-28 Univ Florida State Res Found Processes for the preparation of paclitaxel
US7667055B2 (en) 2005-06-10 2010-02-23 Florida State University Research Foundation, Inc. Processes for the production of polycyclic fused ring compounds
WO2006135656A2 (en) * 2005-06-10 2006-12-21 Florida State University Research Foundation, Inc. Processes for the preparation of paclitaxel
US8242166B2 (en) 2008-03-31 2012-08-14 Florida State University Research Foundation, Inc. C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes
WO2012117417A1 (en) * 2011-02-28 2012-09-07 Shilpa Medicare Limited Process for preparing (2r, 3s) 2-benzyloxy-3-tert-butoxy carbonyl amino-3-phenyl propionic acid
CN103086924A (en) * 2013-01-17 2013-05-08 暨明医药科技(苏州)有限公司 Synthetic method of docetaxel and intermediate of docetaxel
WO2016140104A1 (en) * 2015-03-03 2016-09-09 東レ・ファインケミカル株式会社 3-phenylisoserine derivative production method
US10087139B2 (en) 2015-03-03 2018-10-02 Toray Fine Chemicals Co., Ltd. 3-Phenylisoserine derivative production method

Also Published As

Publication number Publication date
AU6646496A (en) 1997-03-12
US5760251A (en) 1998-06-02

Similar Documents

Publication Publication Date Title
EP0956284B1 (en) Process for selective derivatization of taxanes
US5808113A (en) Preparation of Taxol and docetaxel through primary amines
US5760251A (en) Taxol process and compounds
EP0832080B9 (en) Paclitaxel synthesis from precursor compounds and methods of producing the same
US6500966B1 (en) Process for the preparation of taxanes from 10-deacetylbaccatin III
EP0847393B1 (en) Paclitaxel synthesis from precursor compounds and methods of producing the same
US6020507A (en) Synthesis of paclitaxel from baccatin III by protection of the 7-hydroxyl of baccatin III using a strong base and an electrophile
EP0837846B1 (en) C-2' hydroxyl-benzyl protected, n-carbamate protected (2r,3s)-3-phenylisoserine and production process therefor
EP1049686B9 (en) Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
US7759494B2 (en) Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxy-carbonyl]-5-oxazolidine carboxylic acids
KR20070108181A (en) Method for preparing paclitaxel
KR100846891B1 (en) A process for the preparation of paclitaxel
RU2326876C2 (en) Method of paclitaxel preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA